
Millendo Therapeutics, Inc. MLND
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
1.27 M |
Market Cap[1] |
$ 20.2 M |
EBITDA (LTM) |
$ 1.05 B |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Фармсинтез
LIFE
|
- | - | - | MOEX | ||
|
Atara Biotherapeutics
ATRA
|
$ 6.85 | 5.38 % | $ 85.9 M | Nasdaq Global Select Market,SPB | ||
|
Oncternal Therapeutics
ONCT
|
- | -24.12 % | $ 1.56 M | Nasdaq Capital Market | ||
|
Actinium Pharmaceuticals
ATNM
|
$ 1.09 | -19.26 % | $ 34 M | NYSE American | ||
|
Axon Enterprise
AXON
|
$ 300.63 | 0.68 % | $ 23.5 B | Nasdaq Global Select Market,SPB | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
MannKind Corporation
MNKD
|
$ 4.08 | 0.12 % | $ 1.25 B | Nasdaq Global Market | ||
|
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | ||
|
Histogen
HSTO
|
- | 31.6 % | $ 2.12 M | Nasdaq Global Select Market | ||
|
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | ||
|
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
- | - | $ 1.62 B | NYSE | ||
|
PhaseBio Pharmaceuticals
PHAS
|
- | 7.4 % | $ 6.29 M | Nasdaq Global Market | ||
|
Forma Therapeutics Holdings
FMTX
|
- | - | $ 958 M | Nasdaq Global Market | ||
|
Blueprint Medicines Corporation
BPMC
|
- | - | $ 8.14 B | Nasdaq Global Select Market,SPB | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
- | - | $ 26.6 B | Nasdaq Global Select Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 1.48 | -3.27 % | $ 2.44 M | NYSE American | ||
|
Provention Bio
PRVB
|
- | - | $ 2.37 B | Nasdaq Global Select Market | ||
|
Reata Pharmaceuticals
RETA
|
- | - | $ 6.29 B | Nasdaq Global Market,SPB | ||
|
Rhythm Pharmaceuticals
RYTM
|
$ 119.1 | 2.14 % | $ 7.74 B | Nasdaq Global Market,SPB | ||
|
iTeos Therapeutics
ITOS
|
- | - | $ 411 M | Nasdaq Global Market | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 2.76 | -8.35 % | $ 36.8 M | Nasdaq Global Market | ||
|
PolarityTE
PTE
|
- | -0.82 % | $ 1.78 M | Nasdaq Capital Market | ||
|
Kronos Bio
KRON
|
- | 1.49 % | $ 50.8 M | Nasdaq Global Select Market | ||
|
Cullinan Management
CGEM
|
$ 9.01 | -2.86 % | $ 543 M | Nasdaq Global Select Market | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
$ 54.13 | 2.46 % | $ 151 M | Nasdaq Global Select Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Trevena
TRVN
|
- | -46.58 % | $ 31.8 M | Nasdaq Capital Market | ||
|
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | ||
|
Molecular Templates
MTEM
|
- | -23.43 % | $ 495 K | Nasdaq Capital Market | ||
|
Oncorus
ONCR
|
- | -8.54 % | $ 3.19 M | Nasdaq Global Market | ||
|
BioXcel Therapeutics
BTAI
|
$ 0.07 | 9.81 % | $ 855 K | Nasdaq Global Select Market,SPB | ||
|
Novan
NOVN
|
- | -24.84 % | $ 2.64 M | Nasdaq Capital Market | ||
|
CohBar
CWBR
|
- | -15.44 % | $ 2.2 M | Nasdaq Capital Market | ||
|
NeuBase Therapeutics
NBSE
|
- | -1.56 % | $ 12.3 M | Nasdaq Global Select Market | ||
|
Epizyme
EPZM
|
- | - | $ 249 M | Nasdaq Global Select Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Scopus BioPharma
SCPS
|
- | -48.37 % | $ 3.71 M | Nasdaq Global Select Market | ||
|
Nabriva Therapeutics plc
NBRV
|
- | - | $ 4.55 M | Nasdaq Global Select Market | ||
|
Annovis Bio
ANVS
|
$ 0.81 | 9.63 % | $ 16.6 M | NYSE American | ||
|
scPharmaceuticals
SCPH
|
- | - | $ 218 M | Nasdaq Global Select Market | ||
|
X4 Pharmaceuticals
XFOR
|
$ 3.02 | -2.27 % | $ 128 M | Nasdaq Capital Market | ||
|
Entasis Therapeutics Holdings
ETTX
|
- | - | $ 105 M | Nasdaq Global Market | ||
|
Citius Pharmaceuticals
CTXR
|
$ 0.52 | -0.62 % | $ 5.75 M | Nasdaq Capital Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Global Blood Therapeutics
GBT
|
- | - | $ 4.62 B | Nasdaq Global Select Market,SPB | ||
|
Inozyme Pharma
INZY
|
- | - | $ 207 M | Nasdaq Global Select Market | ||
|
NanoString Technologies
NSTG
|
- | -37.43 % | $ 5.1 M | Nasdaq Global Select Market | ||
|
Evogene Ltd.
EVGN
|
$ 0.36 | 5.82 % | $ 2.83 M | Nasdaq Global Market | ||
|
Humanigen
HGEN
|
- | -81.12 % | $ 4.28 M | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.